CDKN2C Antibody / Cyclin-dependent kinase inhibitor 2C, 100 ug

CDKN2C antibody detects Cyclin-dependent kinase inhibitor 2C, a member of the INK4 family of tumor suppressors that regulate cell cycle progression. Encoded by the CDKN2C gene on chromosome 1p32.3, this protein inhibits cyclin-dependent kinases CDK4 and CDK6, preventing phosphorylation of the retinoblastoma (RB) protein and blocking the G1-to-S phase transition. By enforcing this checkpoint, CDKN2C maintains proper cell cycle control and prevents uncontrolled proliferation in both normal and cancerous tissues.

CDKN2C, also known as p18INK4C, is composed of ankyrin repeat domains that mediate specific binding to CDKs, thereby blocking their interaction with D-type cyclins. Through this inhibition, CDKN2C contributes to cell differentiation, growth arrest, and senescence. It is particularly active in hematopoietic, endocrine, and neural cells, where it coordinates cell cycle exit during differentiation.

The CDKN2C antibody is widely used in cancer biology, cell cycle regulation, and molecular pathology research to study proliferation control, checkpoint activation, and tumor suppression. Western blot analysis identifies a 19 kilodalton band corresponding to CDKN2C, while immunohistochemistry demonstrates nuclear staining in differentiated and quiescent cells. This antibody enables examination of INK4-mediated CDK inhibition and its effects on proliferation and differentiation pathways.

Loss or downregulation of CDKN2C is associated with multiple cancers, including glioma, pituitary adenoma, and leukemia, often through deletion or promoter methylation. Conversely, overexpression can contribute to cell cycle arrest and growth suppression. The CDKN2C antibody provides a dependable tool for studying tumor suppressor networks and checkpoint control. NSJ Bioreagents offers this antibody validated for its applications, ensuring consistent results in studies of cell cycle and tumor regulation.